CNS Pharmaceuticals, Inc. (CNSP)
4.97
+0.22
(+4.63%)
USD |
NASDAQ |
Oct 23, 16:00
4.97
0.00 (0.00%)
After-Hours: 20:00
CNS Pharmaceuticals Enterprise Value : -12.72M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -12.72M |
| October 22, 2026 | -13.04M |
| October 21, 2026 | -12.93M |
| October 20, 2026 | -12.69M |
| October 19, 2026 | -12.69M |
| October 16, 2026 | -12.90M |
| October 15, 2026 | -12.42M |
| October 14, 2026 | -12.17M |
| October 13, 2026 | -12.17M |
| October 12, 2026 | -12.40M |
| October 09, 2026 | -12.17M |
| October 08, 2026 | -12.17M |
| October 07, 2026 | -12.05M |
| October 06, 2026 | -12.24M |
| October 05, 2026 | -12.24M |
| October 02, 2026 | -12.20M |
| October 01, 2026 | -12.33M |
| September 30, 2026 | -12.24M |
| September 29, 2026 | -12.81M |
| September 28, 2026 | -12.52M |
| September 25, 2026 | -12.78M |
| September 24, 2026 | -12.46M |
| September 23, 2026 | -12.46M |
| September 22, 2026 | -12.33M |
| September 21, 2026 | -12.36M |
| Date | Value |
|---|---|
| September 18, 2026 | -12.52M |
| September 17, 2026 | -12.50M |
| September 16, 2026 | -11.95M |
| September 15, 2026 | -11.66M |
| September 14, 2026 | -11.66M |
| September 11, 2026 | -11.45M |
| September 10, 2026 | -11.58M |
| September 09, 2026 | -11.54M |
| September 08, 2026 | -11.30M |
| September 04, 2026 | -11.61M |
| September 03, 2026 | -11.38M |
| September 02, 2026 | -11.20M |
| September 01, 2026 | -11.37M |
| August 31, 2026 | -11.25M |
| August 28, 2026 | -11.91M |
| August 27, 2026 | -11.92M |
| August 26, 2026 | -12.04M |
| August 25, 2026 | -11.51M |
| August 24, 2026 | -11.30M |
| August 21, 2026 | -11.46M |
| August 20, 2026 | -11.22M |
| August 19, 2026 | -11.46M |
| August 18, 2026 | -11.42M |
| August 17, 2026 | -12.09M |
| August 14, 2026 | -11.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.588M |
| Total Expenses (Quarterly) | 2.588M |
| EPS Diluted (Quarterly) | -0.3785 |
| Earnings Yield | -474.7% |
| Normalized Earnings Yield | -474.68 |